In SURMOUNT-1 , a 72-week Phase 3 double-blind trial in 2,539 adults with obesity (or overweight with a complication) but without diabetes, once-weekly tirzepatide produced mean weight changes of 15.0% (5 mg), 19.5% (10 mg), and 20.9% (15 mg) versus 3.1% with placebo, with 5057% of participants on the higher doses losing at least 20% of body weight
[DOI] [PMC free article] [PubMed] [Google Scholar] Rea I.M., McMaster D., Donnelly J., McGrath L.T., Young I.S
Reduces melanin production: Alpha arbutin effectively inhibits tyrosinase, the enzyme responsible for melanin production, resulting in a brighter complexion
Glutathione for liver health Glutathione supports both Phase 1 and Phase 2 Detoxification pathways